Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBIT (2021 - 2025)

Historic EBIT for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$54.0 million.

  • Prime Medicine's EBIT rose 47.76% to -$54.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$204.0 million, marking a year-over-year increase of 986.53%. This contributed to the annual value of -$202.5 million for FY2024, which is 113.53% up from last year.
  • Per Prime Medicine's latest filing, its EBIT stood at -$54.0 million for Q3 2025, which was up 47.76% from -$53.4 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's EBIT ranged from a high of -$10.4 million in Q3 2021 and a low of -$68.0 million during Q4 2023
  • Moreover, its 5-year median value for EBIT was -$48.3 million (2024), whereas its average is -$44.4 million.
  • Examining YoY changes over the last 5 years, Prime Medicine's EBIT showed a top increase of 3560.49% in 2022 and a maximum decrease of 20358.68% in 2022.
  • Prime Medicine's EBIT (Quarter) stood at -$60.1 million in 2021, then surged by 35.6% to -$38.7 million in 2022, then tumbled by 75.89% to -$68.0 million in 2023, then surged by 35.01% to -$44.2 million in 2024, then dropped by 22.05% to -$54.0 million in 2025.
  • Its EBIT was -$54.0 million in Q3 2025, compared to -$53.4 million in Q2 2025 and -$52.4 million in Q1 2025.